You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR CYMBALTA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for CYMBALTA

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00105989 ↗	Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder	Completed	Boehringer Ingelheim	Phase 3	2005-03-01	The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00105989 ↗	Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder	Completed	Eli Lilly and Company	Phase 3	2005-03-01	The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00114127 ↗	Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome	Completed	Massachusetts General Hospital	Phase 3	2004-06-01	The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.
NCT00177671 ↗	Antidepressant Medication Plus Donepezil for Treating Late-life Depression	Completed	National Institute of Mental Health (NIMH)	Phase 4	2003-12-01	This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CYMBALTA

Condition Name

Chart
Table

Condition Name for CYMBALTA
Intervention	Trials
Major Depressive Disorder	22
Depression	15
Fibromyalgia	9
Generalized Anxiety Disorder	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CYMBALTA
Intervention	Trials
Depression	48
Depressive Disorder	44
Depressive Disorder, Major	33
Disease	28
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CYMBALTA

Trials by Country

Map
Table

Trials by Country for CYMBALTA
Location	Trials
United States	514
Canada	29
Germany	12
France	12
United Kingdom	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CYMBALTA
Location	Trials
New York	30
California	28
Florida	25
Ohio	25
Texas	21
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CYMBALTA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CYMBALTA
Clinical Trial Phase	Trials
Phase 4	60
Phase 3	37
Phase 2/Phase 3	3
[disabled in preview]	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CYMBALTA
Clinical Trial Phase	Trials
Completed	100
Recruiting	16
Unknown status	9
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CYMBALTA

Sponsor Name

Chart
Table

Sponsor Name for CYMBALTA
Sponsor	Trials
Eli Lilly and Company	67
Boehringer Ingelheim	12
Shionogi	8
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CYMBALTA
Sponsor	Trials
Industry	105
Other	104
NIH	11
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.